Reports & Guidelines
Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD)
This Phase 3 clinical study compares the efficacy and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4/6 inhibitor in combination with fulvestrant or an aromatase inhibitor (AI).
Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer – Full Text View.
Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous balixafortide given with eribulin versus eribulin alone in the treatment of HER2 negative, Locally Recurrent or Metastatic Breast Cancer.
CDN CANCER SOCIETY REPORTS, June 2018
Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
July 2018 ESMO Guidelines for MBC from Lisbon Conference 2017
To assist those using and/or evaluating the ESMO Clinical Practice Guidelines, download the methodology here
2017-10 Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010
Differences in de novo (dnMBC) and recurrent metastatic breast cancer (rMBC) presentation and survival over time have not been adequately described.A retrospective cohort study, 1990–2010, with follow up through 2015 of dnMBC patients …
Spatiotemporal progression of metastatic breast cancer: a Markov chain model highlighting the role of early metastatic sites
A new model can forecast if breast cancer will spread to other sites in the body, as well as the most likely pathway. Metastasis – the spread of tumors to other tissues – was assumed to be unpredictable. Paul Newton at the University of Southern California, United States, and colleagues used data from 446 patients,…
Perspective on the interpretation of research and translation to clinical care with therapy-associated metastatic breast cancer progression as an example, Beth Caldwell, Co-Author
2018/02 Triple Negative Breast Cancer: New Subtype Classifications Sheds Light on Targeted Treatments
Triple negative breast cancer (TNBC) is so named because TNBC cells lack the three common breast tumor markers: estrogen receptor, progesterone receptor and the HER2 protein. Unlike breast cancers with these markers, there are currently no FDA-approved targeted therapies for TNBC.
2016 Emerging strategies for treating brain metastases from breast cancer
Brain metastasis is an end stage in breast cancer progression. Traditional treatment options have minimal efficacy, and overall survival is on the order of months. The incidence of brain metastatic disease is increasing with the improved management of …
2018 AACR Annual Meeting 2018: Opening Plenary Session on Liquid Biopsy, Immunotherapy, and More
The AACR Annual Meeting 2018 kicked off on Sunday in Chicago. Presenters in the Opening Plenary session offered a preview of some of the cutting-edge cancer research that will be discussed this week.
Hormone-fueled breast cancer cells halted with new approach
Scientists identify where hormone-fueled breast cancer cells derive their energy from, and they find a way to block their access to it.
Cancer breakthrough: Novel approach can ‘starve’ tumors to death
Current research investigates the potential of an experimental compound in causing cancer cell ‘starvation’ by depriving them of access to a key nutrient.
Breast cancer: Protein that drives metastasis uncovered
Researchers find a specific protein that helps breast cancer tumors to spread and use a combined form of therapy to reduce metastasis in mice.
Receptor Conversion in Distant Breast Cancer Metasticies
PubMed comprises more than 29 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Targeting protein quality control pathways in breast cancer
The efficient production, folding, and secretion of proteins is critical for cancer cell survival. However, cancer cells thrive under stress conditions that damage proteins, so many cancer cells overexpress molecular chaperones that facilitate protein folding and target misfolded proteins for degradation via the ubiquitin-proteasome or autophagy pathway. Stress response pathway induction is also important for…
Aspirin, lysine, mifepristone and doxycycline combined can effectively and safely prevent and treat cancer metastasis: prevent seeds from gemmating on soil
Recent scientific advances have increased our understanding of the cancer metastatic complexities and provided further impetus for new combination therapies to prevent cancer metastasis. Here, we demonstrated that a combination (HAMPT) of aspirin, lysine, …
Science 37 and Novartis Sign Strategic Alliance to Advance Decentralized Clinical Trials
Science 37, a trailblazing company focused on “site-less” clinical trials, announced today a strategic alliance with Novartis.